Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy

Cancer Immunology, Immunotherapy

Volumn 64, Issue 6, 2015, Pages 655-663

  Mulders, Peter F ^a   De Santis, Maria ^b   Powles, Thomas ^c   Fizazi, Karim ^d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Immunotherapy; Metastatic castration resistant prostate cancer; Prostate cancer; Sipuleucel T

Indexed keywords

SIPULEUCEL T; CANCER VACCINE; TISSUE EXTRACT;

CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL STUDY; DATA SYNTHESIS; DISEASE MARKER; DRUG MANUFACTURE; EVIDENCE BASED PRACTICE; HUMAN; IMMUNE RESPONSE; MALE; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; IMMUNOLOGY; IMMUNOTHERAPY; METASTASIS; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TISSUE EXTRACTS;

EID: 84930418694     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1707-3     Document Type: Review

References (37)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403
2. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29
3. Horwich A, Hugosson J, de Reijke T, Panel members: European Society for Medical Oncology et al (2013) Prostate cancer: ESMO consensus conference guidelines 2012. Ann Oncol 24(Suppl 5):1141–1162
4. Hotte SJ, Saad F (2010) Current management of castrate-resistant prostate cancer. Curr Oncol 17(Suppl 2):S72–S79
5. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422
6. Kantoff PW, Schuetz TJ, Blumenstein BA et al (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28:1099–1105
7. Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148
8. Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197
9. Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223
10. Kwon ED, Drake CG, Scher HI et al (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15:700–712
11. Dendreon Corporation. PROVENGE (sipuleucel-T) prescribing information. http://www.dendreon.com/prescribing-information.pdf. Accessed 27 Oct 2014
12. Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089–3094
13. Higano CS, Schellhammer PF, Small EJ et al (2009) Integrated data from two randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670–3679
14. ® (sipuleucel-T) summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002513/WC500151099.pdf. Accessed 27 Oct 2014
15. Small EJ, Wesley JD, Quinn D et al (2012) Antigen-presenting cell (APC) activation in sipuleucel-T: is activation increased in early prostate cancer disease states? European Society for Medical Oncology (ESMO) Congress, Vienna, Austria, September 28–October 2, 2012. Poster No. 942
16. Hall SJ, Klotz L, Pantuck AJ et al (2011) Integrated safety data from four randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol 186:877–881
17. Drake CG (2010) Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 10:580–593
18. Sheikh NA, Jones LA (2008) CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother 57:1381–1390
19. Sheikh NA, Petrylak D, Kantoff PW et al (2013) Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 62:137–147
20. Sheikh N, Perdue N, Trager J, Haynes H, Guhathakurta D, Kandadi H (2013) Integrated analysis of immunological profiles during manufacture of sipuleucel-T. FOCiS 2013. Abstract No. S78. http://www.focisnet.org/images/events/focis2013/Abstract%20Supplement_FINAL_06272013.pdf. Accessed 27 Oct 2014
21. Fong L, Weinberg V, Chan S et al (2012) Neoadjuvant sipuleucel-T in localised prostate cancer: effects on immune cells within the prostate tumour microenvironment. European Society for Medical Oncology (ESMO) Congress, Vienna, Austria, September 28–October 2, 2012. Poster No. 939
22. McNeel D, Gardner TA, Higano CS et al (2014) A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. Cancer Immunol Res 10:988–999
23. Jacobsen EA, Helmers RA, Lee JJ, Lee NA (2012) The expanding role of eosinophil(s) in health and disease. Blood 120:3882–3890
24. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
25. Madan RA, Schwaab T, Gulley JL (2012) Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. J Natl Compr Canc Netw 10:1505–1512
26. Gulley JL, Drake CG (2011) Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res 17:3884–3891
27. Huber ML, Haynes L, Parker C, Iversen P (2012) Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 104:273–279
28. Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF (2012) On behalf of the IMPACT authors. RE: interdisciplinary critique of sipuleucel-t as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 104(14):1107–1109
29. Drake CG (2012) RE: Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer. J Natl Cancer Inst 104(18):1422
30. Gulley JL, Leitman SF, Dahut W, Schlom J (2012) RE: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 104(14):1106
31. Sheikh NA, Small EJ, Quinn DI et al (2012) Sipuleucel-T product characterization across different disease states of prostate cancer. J Clin Oncol 30(Suppl 5). Abstr. No. 42
32. Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW (2013) Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 81:1297–1302
33. Small EJ, Higano CS, Kantoff PW et al (2014) Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. Prostate Cancer Prostatic Dis 17:259–264
34. Schlom J (2012) Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 104:599–613
35. Petrylak DP, Dawson NA, Gardner T et al (2010) Persistence of immunotherapy survival effects of sipuleucel-T and relationship to postrandomization docetaxel use in phase III studies. J Clin Oncol 28(Suppl 15). Abstr. No. 4551
36. Small EJ, Lance R, Gardner TA et al (2013) A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol 31(Suppl 6). Abstr. No. 114
37. Antonarakis ES, Kibel AS, Adams G, et al. (2013) A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results. J Clin Oncol 31, 2013 (suppl; abstr 5016)